Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies that merge medicine with technology, and have the potential to transform therapeutic categories.
We focus our efforts on serious diseases that are prevalent and poorly controlled. Our near-term goal is to deliver a game-changing new level of freedom for a vast number of patients with type 2 diabetes. Making real differences in these two areas is our future and our passion.
At Intarcia, through the passion and commitment of our employees, we seek to leverage our technologies in drug development and delivery to provide improved therapeutic outcomes for patients and to help patients achieve a better quality of life.
Our values form the core of our business. They are the key character traits that distinguish who we are, how we operate, and how we treat each other. Our values must be visible every day − in our operations, our decisions, our policies, and our interactions.
Intarcia’s lead product candidate, ITCA 650 (continuous subcutaneous delivery of exenatide), is currently in Phase 3 development for the treatment of type 2 diabetes. Three Phase 3 studies have been successfully completed, and one is ongoing. Intarcia expects to file for regulatory approval of ITCA 650 in the U.S. in 2016.
Our artwork is a metaphor for how we work – unleashing our talent so we can create the keys to unlock innovation so disruptive it changes the standards by which things are done, generating tremendous benefit to patients, payors and providers.
Intarcia carefully maintains an environment based on our core values of innovation and integrity. We are comprised of talented and entrepreneurial people who enjoy collaborating and achieving excellent results. Our leaders are deeply experienced and extremely approachable executives who actively support our business plan and our team. Read more